Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2020-03-11 DOI:10.2217/mmt-2020-0001

Amy C Schefler, Alison Skalet, Scott Cn Oliver, John Mason, Anthony B Daniels, Katherina M Alsina, Kristen M Plasseraud, Federico A Monzon, Brian Firestone

{"title":"Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling.","authors":"Amy C Schefler, Alison Skalet, Scott Cn Oliver, John Mason, Anthony B Daniels, Katherina M Alsina, Kristen M Plasseraud, Federico A Monzon, Brian Firestone","doi":"10.2217/mmt-2020-0001","DOIUrl":null,"url":null,"abstract":"Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2020-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2020-0001","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2020-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 9

Abstract

Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.

Abstract Image

查看原文本刊更多论文

基因表达谱对葡萄膜黑色素瘤患者风险管理的前瞻性评价。

目的:DecisionDx-UM基因表达测定结果的临床应用研究旨在评估15基因表达谱(15-GEP)检测在葡萄膜黑色素瘤(UM)患者中的临床应用，这是一项大型、前瞻性多中心队列研究。患者和方法:9个中心前瞻性纳入138例接受15-GEP临床试验的UM患者。收集了医生推荐的专科转诊和转移性监测方案。结果:高危2级患者中有93%转诊到内科肿瘤科接受随访，而高危1级患者中这一比例为51%。大多数(62%)2类患者建议进行总体高强度转移性监测，而85%的1类患者建议进行低强度转移性监测。结论:UM患者的治疗方案建议与gep通知的转移风险一致，与先前的研究一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.